|1.||Tsuji, Masakatsu: 2 articles (02/2004 - 08/2003)|
|2.||Page, Malcolm G P: 1 article (08/2004)|
|3.||Miyazaki, Shuichi: 1 article (02/2004)|
|4.||Okazaki, Kenichi: 1 article (02/2004)|
|5.||Yamaguchi, Keizo: 1 article (02/2004)|
|6.||Kuwahara, Shogo: 1 article (08/2003)|
|7.||Shimada, Jingoro: 1 article (08/2003)|
|8.||Miwa, Hideaki: 1 article (08/2003)|
|9.||Takema, Morio: 1 article (08/2003)|
08/01/2003 - "High levels of S-3578 were detected in plasma in vivo, and its efficacy against experimentally induced infections in mice caused by MRSA and P. "
08/01/2003 - "S-3578 (10 mg/kg) induced a significant reduction in the numbers of viable MRSA SR17764 and Pseudomonas aeruginosa SR10396 organisms in polymicrobial pulmonary infections. "
02/01/2004 - "Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection models."
08/01/2003 - "We conclude that S-3578 is a promising new cephalosporin for the treatment of infections caused by gram-positive and -negative bacteria, including MRSA and P. "
08/01/2003 - "In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models."
|2.||Body Weight (Weight, Body)
|4.||Cross Infection (Nosocomial Infection)
08/01/2004 - "At least two of these, BAL-5788 and S-3578, also have Gram-negative activity, which is comparable to that of the third-and fourth-generation cephalosporins, making them broad-spectrum agents that could be used in hospital infections where methicillin-resistant staphylococci is likely to be present."
|3.||Cephalosporins (Cephalosporin Antibiotics)